Trial of Onco-Panel for Geneprofiling to Estimate both Adverse events and Response by cancer treatment

Conditions

Cancer patient who will receive chemotherapy

Kubo T, Sunami K, Koyama T, Kitami M, Fujiwara Y, Kondo S, Yonemori K, Noguchi E, Morizane C, Goto Y, Maejima A, Iwasa S, Hamaguchi T, Kawai A, Namikawa K, Arakawa A, Sugiyama M, Ohno M, Yoshida T, Hiraoka N, Yoshida A, Yoshida M, Nishino T, Furukawa E, Narushima D, Nagai M, Kato M, Ichikawa H, Fujiwara Y, Kohno T, Yamamoto N.

2024-04-1212 citations

10.1016/j.esmoop.2024.102981

Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants

Ayumu Arakawa, Hitoshi Ichikawa, Takashi Kubo, Noriko Motoi, Tadashi Kumamoto et al. (33 authors)

New England Journal of Medicine2021-01-0658 citations

10.1056/nejmoa2030391

Targeted-sequencing in rare cancers and the impact on patient treatment.

Hitomi Sumiyoshi Okuma, Takashi Kubo, Hitoshi Ichikawa, Takashi Kohno, Takaaki Mizuno et al. (14 authors)

Journal of Clinical Oncology2019-05-203 citations

10.1200/jco.2019.37.15_suppl.e14755

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Cancer patient who will recieve chemotherapy 2) Age over 1 year 3) Samples meeting one of the followings: 3)-1Tumor tissue i) Surplus sample stored in the NCC biobank ii) Surplus sample of diagnostic biopsy iii) Surgical surplus tumor sample iv) Newly-taken tumor sample for this study 3)-2 Non-tumor tissue i) Surplus tissue and blood in the NCC biobank ii) Newly-taken blood (5-20mL) for this study iii) Newly-taken oral mucosa for this study iv) Newly-taken non-tumor gastrointestinal mucosa for this study 4) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Judged ineligible by the clinical investigators

Design outcomes

Primary

Measure	Time frame
Analysis of somatic gene mutation, gene expression of tumor tissue	—

Secondary

Measure	Time frame
Polymorphism analysis of genes related to the pharmacodynamics and pharmacokinetics in non-tumor tissue	—

Countries

Japan

Contacts

Public ContactShunsuke Kondo

National Cancer Center Hospital Department of Experimental Therapeutics

shkondo@ncc.go.jp03-3542-2511

Outcome results